8-K: ZyVersa Therapeutics Changes Accounting Firms: Marcum LLP Replaced by CBIZ CPAs

ZyVersa Therapeutics announces the resignation of Marcum LLP as its independent auditor and the engagement of CBIZ CPAs, effective April 7, 2025, following Marcum's acquisition by CBIZ CPAs.

Summary

• ZyVersa Therapeutics has changed its independent registered public accounting firm from Marcum LLP to CBIZ CPAs.
• The change was effective April 7, 2025, following CBIZ CPAs' acquisition of Marcum's attest business on November 1, 2024.
• Marcum resigned on April 4, 2025, and the Audit Committee approved the engagement of CBIZ CPAs.
• Marcum's reports on the company's financial statements for the fiscal years ended December 31, 2024 and 2023, included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
• The company identified material weaknesses in its internal control over financial reporting as of December 31, 2024 and 2023.

Sentiment

Score: 4

Explanation: The change in auditors itself is neutral, but the disclosure of a going concern and material weaknesses in internal control is concerning, leading to a slightly negative sentiment.

Positives

• The transition to CBIZ CPAs appears to be a smooth one, with no reported disagreements on accounting principles or practices.
• Marcum provided a letter to the SEC agreeing with the company's statements regarding the change in accounting firms.

Negatives

• Marcum's audit reports for 2024 and 2023 included an explanatory paragraph about the company's ability to continue as a going concern.
• The company identified material weaknesses in its internal control over financial reporting as of December 31, 2024 and 2023.

Risks

• The material weaknesses in internal control over financial reporting could lead to future financial misstatements.
• The going concern note in previous audit reports indicates potential financial instability.

Future Outlook

The document does not contain any specific forward-looking statements or guidance regarding future financial performance.

Industry Context

Changes in accounting firms are not uncommon, especially following acquisitions or mergers within the accounting industry. Companies often seek to align themselves with firms that have specific expertise or a better understanding of their business.

Comparison to Industry Standards

• The engagement of a new auditor after an acquisition of the previous auditor's practice is a standard procedure.
• The disclosure of material weaknesses in internal control is consistent with regulatory requirements for public companies.
• The inclusion of a going concern paragraph in an audit report is a serious matter and is not unique to ZyVersa, but it does highlight potential financial challenges.

Stakeholder Impact

• Shareholders may be concerned about the going concern qualification and material weaknesses in internal control.
• Creditors may reassess the company's creditworthiness due to the going concern qualification.

Key Dates

Keywords

accounting firm, CBIZ CPAs, Marcum LLP, independent auditor, financial reporting, internal control, ZyVersa Therapeutics